Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
Source: View publication →
The ASCOT-BPLA trial demonstrated that a newer antihypertensive regimen based on the calcium channel blocker amlodipine prevented more major cardiovascular events, strokes, and all-cause mortality while inducing less diabetes than an older atenolol-based regimen.
Key Findings
Study Design
Study Limitations
Clinical Significance
ASCOT-BPLA fundamentally reshaped global hypertension management. By proving that the amlodipine/perindopril combination was superior to the traditional beta-blocker/thiazide combination for preventing stroke, cardiovascular events, and mortality—while causing fewer metabolic side effects like new-onset diabetes—it prompted international guidelines (including the UK's NICE guidelines) to remove beta-blockers as a preferred first-line therapy for uncomplicated essential hypertension.
Historical Context
For decades, beta-blockers and thiazide diuretics were the undisputed first-line standard for treating hypertension, largely based on older outcome trials. However, observational data hinted that these drugs were not preventing as much coronary heart disease as expected for the degree of blood pressure lowering achieved. The ASCOT trial was conceptualized to test whether newer, metabolically friendlier agents (calcium channel blockers and ACE inhibitors) might confer superior cardioprotection and lower mortality compared to the older drugs, particularly since the vast majority of hypertensive patients eventually require combination therapy.
Guided Discussion
High-yield insights from every perspective
What are the physiological mechanisms by which a calcium channel blocker and an ACE inhibitor combination might be more protective against new-onset diabetes compared to a beta-blocker and thiazide diuretic combination?
Key Response
Atenolol can decrease insulin secretion and sensitivity by blocking beta-2 receptors in the pancreas and skeletal muscle, while thiazides can cause hypokalemia, which impairs insulin release. In contrast, ACE inhibitors can improve insulin sensitivity and CCBs are metabolically neutral, explaining the significantly lower rate of new-onset diabetes in the amlodipine/perindopril arm of ASCOT-BPLA.
A 55-year-old patient with uncomplicated hypertension is currently taking atenolol. Based on the ASCOT-BPLA trial and current guidelines, why is this regimen no longer recommended as first-line therapy, and how would you manage their transition of care?
Key Response
ASCOT-BPLA demonstrated that beta-blockers like atenolol are inferior to CCBs and ACE inhibitors in preventing strokes and major cardiovascular events in uncomplicated hypertension. Residents should recognize that beta-blockers are now reserved for specific indications like heart failure or post-myocardial infarction, and they should safely transition this patient to a CCB, ACEi, or ARB while monitoring for beta-blocker withdrawal.
The ASCOT-BPLA trial noted a significant reduction in stroke in the amlodipine-based arm despite relatively small differences in brachial blood pressure. How does the relationship between central aortic blood pressure and peripheral blood pressure explain this discrepancy?
Key Response
The CAFE substudy of ASCOT revealed that while brachial blood pressures were similar between the two arms, central aortic pressures were significantly lower in the amlodipine/perindopril group. Beta-blockers can increase arterial wave reflection due to bradycardia, failing to lower central aortic pressure as effectively as CCBs/ACE inhibitors, which directly impacts stroke risk and end-organ damage.
The early termination of ASCOT-BPLA highlighted the profound mortality and stroke benefits of the newer regimen. When mentoring trainees, how do you use this trial to teach the concept of 'metabolic penalty' and the importance of looking beyond just the millimeter of mercury when treating hypertension?
Key Response
Attendings can use ASCOT to emphasize that hypertension management is not just about the number on the sphygmomanometer, but also the pleiotropic and metabolic effects of the chosen agents. The atenolol/thiazide regimen exacted a 'metabolic penalty' via increased diabetes and lipid changes, teaching trainees to prioritize regimens that offer comprehensive cardiovascular protection rather than merely lowering peripheral pressure.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
ASCOT-BPLA was stopped prematurely by the Data Safety Monitoring Board due to significant differences in all-cause mortality and stroke. What are the statistical risks of stopping a trial early for benefit, and how does this impact the precision of the estimated treatment effect for secondary endpoints?
Key Response
Stopping a trial early for benefit can lead to an overestimation of the treatment effect, often called 'truncation bias' or a 'random high,' because trials are often stopped at a peak of random variation. PhDs must critically evaluate how early termination reduces statistical power to detect differences in secondary endpoints, limits long-term safety data, and requires rigorous stopping boundaries like O'Brien-Fleming to prevent Type I error inflation.
If you were peer-reviewing ASCOT-BPLA, how would you scrutinize the PROBE (Prospective Randomized Open, Blinded Endpoint) design of the trial and its potential to introduce performance or detection bias?
Key Response
While the PROBE design is pragmatic and endpoints in ASCOT were adjudicated blindly, the open-label treatment could influence physician behavior, such as the differential prescription of non-study medications like statins, or patient reporting of subjective side effects. A rigorous reviewer would demand sensitivity analyses adjusting for these potential confounders to ensure the open-label nature did not drive the outcome differences.
How did the findings of the ASCOT-BPLA trial directly influence the downgrade of beta-blockers in major hypertension guidelines such as the ACC/AHA and NICE guidelines, and what level of evidence does this represent for modern recommendations?
Key Response
ASCOT-BPLA provided crucial Level A evidence that was pivotal in the NICE and ACC/AHA decisions to remove beta-blockers from first-line therapy for primary hypertension. The trial demonstrated that beta-blocker/thiazide regimens yield inferior cardiovascular outcomes and higher diabetes risk compared to CCB/ACEi combinations, forming the cornerstone of the modern A/C/D (ACEi/ARB, CCB, Diuretic) primary treatment algorithms.
Clinical Landscape
Noteworthy Related Trials
ALLHAT Trial
Tested
Amlodipine, lisinopril, or doxazosin
Population
Hypertensive patients aged 55 or older with at least one other CHD risk factor
Comparator
Chlorthalidone
Endpoint
Fatal CHD or nonfatal MI
VALUE Trial
Tested
Valsartan-based regimen
Population
Hypertensive patients at high cardiovascular risk
Comparator
Amlodipine-based regimen
Endpoint
Time to first cardiac event
ACCOMPLISH Trial
Tested
Benazepril plus amlodipine
Population
Hypertensive patients at high risk for cardiovascular events
Comparator
Benazepril plus hydrochlorothiazide
Endpoint
Composite of CV death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation, or revascularization
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis